BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 13, 2007
View Archived Issues
As Big Pharma Model Falters, Biotech Rides To The Rescue
Read More
New Virulence Determinant Of Community-Associated MRSA
Read More
Infinity Regains Hedgehog Pathway Inhibitor Program
Read More
Molecular Insight Bond Deal: $150M To Advance Pipeline
Read More
Other News To Note
Read More
Synta's Elesclomol In Pivotal Study In Melanoma Patients
A month after signing a billion-dollar deal with GlaxoSmithKline plc for elesclomol (formerly STA-4783), Synta Pharmaceuticals Corp. kicked off a pivotal Phase III trial of the drug in metastatic melanoma. (BioWorld Today)
Read More
Clinic Roundup
Read More
ACAAI Roundup
Read More